A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2017
Price : $35 *
At a glance
- Drugs Romidepsin (Primary) ; Paclitaxel
- Indications Inflammatory breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Mar 2017 Status changed to discontinued as per sponsor decision.
- 20 Apr 2016 Status changed from recruiting to suspended as contracts need to be renewed.